Analysis revealed a 57% ORR for PD-L1 inhibition in the sufferers having high tumor mutational burden (TMB) and 50% (or greater) PD-L1 expression and a mere 8.7% for those having low TMB and < 1% PD-L1 expression. The gene discussed is CD274; the disease is neoplasm.